UK markets closed

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.52+14.75 (+45.01%)
At close: 04:00PM EST
45.51 -2.01 (-4.23%)
After hours: 06:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close32.77
Open30.43
Bid44.60 x 1100
Ask46.84 x 900
Day's range30.27 - 49.40
52-week range24.16 - 67.84
Volume1,035,087
Avg. volume86,822
Market cap2.729B
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant

    Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage) 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant Saint Herblain (France), January 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laborat

  • Globe Newswire

    VALNEVA Declaration of shares and voting rights - December 31, 2021

    VALNEVA Declaration of shares and voting rights December 31, 2021 __________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 6, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this chang

  • Globe Newswire

    Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

    Saint Herblain (France), January 6, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. As announced in December 20211, the Company commenced rolling submissions for initial approval of VLA2001 with the European Medicines Agency, the UK MHRA and the Bahraini NHRA, and is continuing to work close